Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Free Report) has received an average rating of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $6.14.
A number of equities analysts have commented on the stock. Stifel Nicolaus set a $5.00 target price on shares of Foghorn Therapeutics in a research note on Thursday, October 1st. Weiss Ratings upgraded shares of Foghorn Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, November 9th. Evercore lowered shares of Foghorn Therapeutics from an “outperform” rating to an “in-line” rating and set a $3.00 price target on the stock. in a research report on Tuesday, October 13th. Wall Street Zen upgraded Foghorn Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Wedbush lowered Foghorn Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $10.00 to $2.00 in a research report on Friday, October 2nd.
Check Out Our Latest Analysis on FHTX
Foghorn Therapeutics Stock Down 3.9%
FHTX stock opened at $1.71 on Monday. Foghorn Therapeutics has a 52 week low of $1.66 and a 52 week high of $7.61. The firm has a 50-day simple moving average of $2.50 and a 200-day simple moving average of $4.42. The stock has a market capitalization of $102.53 million, a P/E ratio of 24.43 and a beta of 3.22.
Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $1.04. Foghorn Therapeutics had a net margin of 8.40% and a negative return on equity of 13.46%. The company had revenue of $83.54 million for the quarter, compared to analysts’ expectations of $7.10 million. On average, analysts expect that Foghorn Therapeutics will post -0.07 earnings per share for the current year.
Institutional Trading of Foghorn Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of FHTX. BlackRock Inc. purchased a new position in shares of Foghorn Therapeutics during the second quarter worth $12,819,000. Renaissance Technologies LLC raised its holdings in shares of Foghorn Therapeutics by 36.5% in the 1st quarter. Renaissance Technologies LLC now owns 406,425 shares of the company’s stock valued at $1,943,000 after buying an additional 108,689 shares during the period. Goldman Sachs Group Inc. lifted its stake in Foghorn Therapeutics by 42.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 234,669 shares of the company’s stock worth $838,000 after acquiring an additional 70,413 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Foghorn Therapeutics by 25.6% during the 2nd quarter. Squarepoint Ops LLC now owns 130,346 shares of the company’s stock valued at $636,000 after acquiring an additional 26,603 shares during the period. Finally, SCS Capital Management LLC purchased a new position in Foghorn Therapeutics during the 2nd quarter valued at about $522,000. 61.55% of the stock is currently owned by hedge funds and other institutional investors.
About Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.
Further Reading
- Five stocks we like better than Foghorn Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
